The small molecule NF-κB inhibitor DMF emerged as a promising and well-tolerated CTCL therapeutic in a multicentric clinical phase II study on DMF treatment in relapsed and refractory CTCL patients [24]. Here, NFKB1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.